Abstract
Antimicrobial resistance (AMR) is a growing global health threat that contributes to substantial neonatal mortality. Bangladesh has reported some of the highest rates of AMR among bacteria causing neonatal sepsis. To better understand routes of AMR transmission to newborns, we aimed to characterize the frequency of and risk factors for AMR colonization of mothers and newborns during hospitalization for delivery. We enrolled 177 pregnant women presenting for delivery to a tertiary care hospital in Faridpur, Bangladesh, during February-October 2020. We collected vaginal and rectal swabs from mothers on presentation and after delivery as well as rectal swabs from newborns. We also collected swabs from the hospital environment proximal to the patients. Swabs were plated on chromogenic agars selective for extended-spectrum-beta-lactamase producing organisms (ESBL) and carbapenem-resistant organisms (CRO). We performed univariable and multivariable analyses to determine factors associated with ESBL/CRO colonization. Prior to delivery, 17% of mothers had vaginal colonization and 71% had rectal colonization with ESBLs; 4% had vaginal colonization and 13% had rectal colonization with CROs. Seventy-nine percent of women underwent cesarean deliveries (C-section). Ninety-eight percent of women received prophylactic antibiotics during hospitalization. Following delivery, nearly 90% of mothers and newborns were colonized with ESBLs and over 70% with CROs. Of the 290 environmental samples, 77% were positive for ESBLs, and 69% were positive for CROs. Maternal and newborn colonization at discharge were both associated with C-section (RR for maternal 1.4; 95% CI 1.0-1.8 and newborn 1.3; 95% CI 1.1-1.7). Facility-based deliveries increase exposure to AMR organisms, likely driven by intense use of antibiotics and frequent C-sections. Greater attention should be given to the use of perinatal antibiotics, indications for C-sections, and infection prevention practices to reduce the high prevalence of colonization with antibiotic resistant bacteria.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by NIH FIC Global Health Equity Scholars D43 TW010540 as well as the Thrasher Research Fund (award #15188) (received by AS). http://ghes.berkeley.edu/ https://www.thrasherresearch.org/ The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
icddr,b Research and Ethics Review Committees, Stanford University IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
